Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Frankfurt - Delayed Quote EUR

ALK-Abelló A/S (4AJ0.F)

Compare

21.14

+0.60

+(2.92%)

As of 8:12:07 AM GMT+1. Market Open.

FDA approves ODACTRA® for the treatment of house dust mite allergy in young children

ALK (ALKB:DC / OMX: ALK B) today announced that the US Food and Drug Administration (FDA) has approved ALK’s ODACTRA® tablet for use in young children with house dust mite (HDM) allergy. ODACTRA® is now indicated to treat HDM-induced allergic rhinitis, with or without conjunctivitis, in children aged five through 11, in addition to patients aged 12 through 65. ODACTRA® is an allergy immunotherapy (AIT) tablet which dissolves under the tongue and helps patients reduce their allergy symptoms and t

GlobeNewswire 10 hours ago

AKBLF
0.00%
Alk-Abello AS (AKBLF) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic Expansion

Alk-Abello AS (AKBLF) reports strong growth with a 15% revenue increase for 2024, driven by European tablet sales and strategic initiatives.

GuruFocus.com 8 days ago

ALK-B.CO
Annual General Meeting in ALK-Abelló A/S on 13 March 2025

ALK (ALKB:DC / OMX: ALK B / AKBLF): The Annual General Meeting of ALK-Abelló A/S will take place on Thursday, 13 March 2025 at 4:00 PM (CET) at ALK-Abelló A/S, Bøge Allé 1, 2970 Hørsholm, Denmark. The agenda of the meeting including the complete proposals from the Board of Directors to the AGM is attached. ALK-Abelló A/S For further information please contact: Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525 Media: Maiken Riise Andersen, tel. +45 5054 1434 About ALKALK

GlobeNewswire 8 days ago

AKBLF
0.00%
Annual report 2024: ALK delivers 15% sales growth with profits up 65%

ALK’s (ALKB:DC / OMX: ALK B / AKBLF) Board of Directors has approved the 2024 annual report. Following a robust performance in Q4, full-year results were in line with the latest outlook and represent the best results in the history of the company. ALK expects to continue its growth trajectory and earnings improvement in 2025. Q4 2024 highlights (Comparative figures are shown in brackets. Growth rates are stated in local currencies, unless otherwise indicated) Revenue increased by 11% to DKK 1,49

GlobeNewswire 9 days ago

AKBLF
0.00%
Invitation to the presentation of ALK’s annual report 2024 on Wednesday, 19 February 2025

ALK (ALKB:DC / OMX: ALK B / AKBLF) will publish its annual report for 2024 in the morning on Wednesday, 19 February 2025. Later on the same day, the company will host a presentation for investors and analysts at 1:30 p.m. CET, where ALK’s management will comment on the results and outlook and be available for questions. ALK will be represented by Peter Halling, President & CEO, Claus Steensen Sølje, CFO and Per Plotnikof, VP, Head of IR. Live audio webcast The meeting will be audio webcasted liv

GlobeNewswire 15 days ago

AKBLF
0.00%
ALK’s house dust mite tablet (ACARIZAX®) now recommended by NICE for use in the UK health system

ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the National Institute for Health and Care Excellence (NICE) has recommended the use of ACARIZAX® for the treatment of persistent, moderate to severe house dust mite allergic rhinitis in adults and adolescents. The recommendation paves the way for patients to gain access to ACARIZAX® through the National Health Service (NHS) systems in England, Wales, and Northern Ireland, now making it eligible for general reimbursement. ACARIZAX® is the f

GlobeNewswire 28 days ago

AKBLF
0.00%
3 Stocks Estimated To Be Trading At Discounts Of 26% To 44%

As global markets experience fluctuations with cooling inflation and strong bank earnings propelling U.S. stocks higher, investors are increasingly focused on identifying opportunities amidst these shifting conditions. In this environment, finding undervalued stocks can be a compelling strategy, as they may offer potential value when market sentiment is volatile and certain sectors outperform others.

Simply Wall St. last month

AKBLF
0.00%
METSA.HE

METSB.HE
3 Stocks That May Be Trading Below Estimated Value

In the current climate, global markets are experiencing volatility with U.S. stocks facing declines due to cautious Federal Reserve commentary and political uncertainties, while European and Asian indices also reflect investor apprehension over interest rate outlooks. Amid these fluctuations, identifying stocks that may be trading below their estimated value can offer potential opportunities for investors seeking to capitalize on market inefficiencies. A good stock in this context is one that...

Simply Wall St. 2 months ago

AKBLF
0.00%
CSCCF
ALK – Financial calendar for the 2025 financial year

2025 financial calendar for ALK (ALKB:DC / OMX: ALK B / AKBLF): 22 January 2025: Silent period 19 February 2025: Annual report 2024 13 March 2025 at 4.00 p.m.: Annual General Meeting to be held at ALK Bøge Allé 1 2970 Hørsholm, Denmark Written requests to have specific business transacted at the AGM will be included in the agenda if received by the company on 29 January 2025 at the latest (may be emailed to investor@alk.net) 8 April 2025: Silent period 6 May 2025: Three-month interim report (Q1)

GlobeNewswire 2 months ago

AKBLF
0.00%
Positive results advance peanut tablet to phase II development

ALK’s peanut tablet shown to be safe and tolerable across multiple doses.Development now advances to phase II for dose finding and efficacy. First patients in phase II to receive first doses imminently. Trial expected to complete in 2026. ALK (ALKB:DC / OMX: ALK B) today announced positive interim results from its phase I/II clinical trial (named ‘ALLIANCE’) for its investigational sublingual immunotherapy (‘SLIT’) tablet for the treatment of peanut allergy. This part of the trial, which involve

GlobeNewswire 2 months ago

AKBLF
0.00%
ACARIZAX® approved in Europe for treatment of young children

ALK (ALKB:DC / OMX: ALK B) today announced that its European regulatory filing for ACARIZAX® (house dust mite sublingual allergy immunotherapy tablet) in young children aged five to 11 has been approved by the health authorities in 21 EU countries via a type II variation procedure. The first market introductions, including in ALK’s largest market, Germany, are expected to follow over the coming months. The data that formed the basis for the approval includes results from the largest-ever paediat

GlobeNewswire 2 months ago

AKBLF
0.00%
ALK’s pivotal phase 3 trial in children published in reputable scientific journal

The reputable scientific journal, The Lancet Regional Health – Europe, has published robust results from ALK’s house dust mite sublingual allergy immunotherapy tablet (SLIT-tablet) phase 3 children trial, MT-12, evaluating the efficacy and safety in children (5-11 years) with house dust mite allergic rhinitis.1 With the acceptance for publication, ALK’s MT-12 phase 3 trial has been evaluated by the journal for its methodology, relevance, and clinical implications. This scrutiny helps ensure that

GlobeNewswire 2 months ago

AKBLF
0.00%
Alk-Abello AS (AKBLF) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Improved Margins

Alk-Abello AS (AKBLF) reports robust organic revenue growth and a significant increase in EBIT margin, despite challenges in North America.

GuruFocus.com 3 months ago

ALK-B.CO
3 Stocks That May Be Trading At A Discount Of Up To 41.4%

In the current global market environment, uncertainty surrounding the incoming Trump administration's policies has contributed to volatility, with U.S. stocks experiencing a partial reversal of recent gains and sector returns showing significant variation. As investors navigate these fluctuations and consider potential policy impacts on corporate earnings, identifying stocks that may be undervalued can offer opportunities for those seeking value investments. A good stock in this context is...

Simply Wall St. 3 months ago

AKBLF
0.00%
GJNSF

GJNSY
Nine-month interim report (Q3) 2024 (unaudited)

Company release No. 19/2024 ALK delivers 18% organic revenue growth and an operating profit margin of 23% in Q3 Revenue growth was mainly driven by a continued strong momentum in tablet sales and a recovery in Jext® sales. Europe and International markets were key contributors to growth. The operating profit improved in line with ALK’s financial ambitions, and the full-year outlook remains unchanged. Q3 performance highlights Comparative figures for Q3 2023 are shown in brackets. Revenue growth

GlobeNewswire 3 months ago

AKBLF
0.00%
ARS Pharmaceuticals announces agreement with ALK to commercialize neffy

ARS Pharmaceuticals (SPRY) announced a licensing agreement with ALK-Abello A/S (AKBLF), that provides ALK exclusive rights to commercialize neffy, the first and only needle-free emergency treatment for Type I allergic reactions including anaphylaxis, in Europe, Canada and other geographies outside of the U.S. ARS Pharma retains all rights to neffy in the U.S., and there are no changes to its existing partnerships in Japan, China, Australia and New Zealand. Published first on TheFly – the ultimat

TipRanks 3 months ago

AKBLF
0.00%
SPRY
ALK snags EU and Canada rights to anaphylaxis nasal spray Neffy for $145m

ALK will also pay up to $320m in milestone payments to ARS in the deal, which sees the latter keep rights in the US, Australia, and China.

Pharmaceutical Technology 3 months ago

SPRY

ALK-B.CO

GLDAF
ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)

ALK (ALKB:DC / OMX: ALK B) today announced that it has entered into a strategic license agreement with US-based ARS Pharmaceuticals, Inc. (“ARS Pharma”, NASDAQ: SPRY). The agreement grants ALK exclusive global rights to the neffy® adrenaline (epinephrine) nasal spray, with exception of the USA, Australia, New Zealand, Japan and China. The deal delivers on key elements in ALK’s new strategy Allergy+ and supports ALK’s long-term financial ambitions. Needle-free, nasal delivery of adrenaline has th

GlobeNewswire 3 months ago

AKBLF
0.00%
Invitation to the presentation of ALK’s results for the first nine months (Q3) 2024 on Thursday 14 November 2024

ALK (ALKB:DC / OMX: ALK B / AKBLF) will publish its results for the first nine months (Q3) 2024 in the morning of Thursday 14 November 2024. Later same day, the company will host a presentation for investors and analysts at 1:30 p.m. CET, where ALK’s management will comment on the results for the first nine months and outlook and be available for questions. ALK will be represented by Peter Halling, President & CEO, Claus Steensen Sølje, CFO and Per Plotnikof, VP, Head of IR. Live audio webcast T

GlobeNewswire 3 months ago

AKBLF
0.00%
Alk-Abello AS (AKBLF) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Upgraded Outlook

Alk-Abello AS (AKBLF) reports impressive Q2 performance with 21% organic revenue growth and raises full-year guidance amid robust European sales.

GuruFocus.com 4 months ago

ALK-B.CO

Performance Overview

Return	4AJ0.F	OMX Copenhagen 25 Index
YTD	-0.38%	+4.18%
1-Year	+21.91%	-2.23%
3-Year	+31.96%	+8.06%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

ALK-Abelló A/S (4AJ0.F)

FDA approves ODACTRA® for the treatment of house dust mite allergy in young children

Alk-Abello AS (AKBLF) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic Expansion

Annual General Meeting in ALK-Abelló A/S on 13 March 2025

Annual report 2024: ALK delivers 15% sales growth with profits up 65%

Invitation to the presentation of ALK’s annual report 2024 on Wednesday, 19 February 2025

ALK’s house dust mite tablet (ACARIZAX®) now recommended by NICE for use in the UK health system

3 Stocks Estimated To Be Trading At Discounts Of 26% To 44%

3 Stocks That May Be Trading Below Estimated Value

ALK – Financial calendar for the 2025 financial year

Positive results advance peanut tablet to phase II development

ACARIZAX® approved in Europe for treatment of young children

ALK’s pivotal phase 3 trial in children published in reputable scientific journal

Alk-Abello AS (AKBLF) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Improved Margins

3 Stocks That May Be Trading At A Discount Of Up To 41.4%

Nine-month interim report (Q3) 2024 (unaudited)

ARS Pharmaceuticals announces agreement with ALK to commercialize neffy

ALK snags EU and Canada rights to anaphylaxis nasal spray Neffy for $145m

ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)

Invitation to the presentation of ALK’s results for the first nine months (Q3) 2024 on Thursday 14 November 2024

Alk-Abello AS (AKBLF) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Upgraded Outlook

Performance Overview